US006274170B1

(12) **United States Patent**
Heibel et al.

(10) **Patent No.: US 6,274,170 B1**
(45) **Date of Patent: Aug. 14, 2001**

(54) **COMPOUNDS FOR CARDIOVASCULAR TREATMENT COMPRISING MULTI-VITAMIN AND ANTI-PLATELET AGGREGATING AGENTS AND METHODS FOR MAKING AND USING THE SAME**

(76) Inventors: **Richard Heibel**, 20 N. Port Royal Dr., Hilton Head Island, SC (US) 29928; **John J. Abbott**, 1500 Redfern Dr., Pittsburgh, PA (US) 15241

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/250,941**

(22) Filed: **Feb. 18, 1999**

(51) **Int. Cl.**[7] **A61K 9/58**; A61K 9/60; A61K 9/62

(52) **U.S. Cl.** **424/458**; 424/461; 424/462; 514/772.3; 514/781; 514/782

(58) **Field of Search** 424/464, 489, 424/474, 476, 480, 458, 482, 461, 462, 497, 494, 498, 481

(56) **References Cited**

U.S. PATENT DOCUMENTS

1,969,998	8/1934	Wodlinger .
3,914,419	10/1975	Haeger et al. .
4,753,926	6/1988	Lucas et al. .
4,760,080	7/1988	Barron et al. .
4,806,354	2/1989	Green .
4,937,234	6/1990	Fahim .
4,945,083	7/1990	Jansen, Jr. .
5,084,482	1/1992	Hirsch et al. .
5,118,505	6/1992	Költringer .
5,300,298	4/1994	LaNoue .
5,322,689	6/1994	Hughes et al. .
5,401,730	3/1995	Sauvage et al. .
5,541,220	7/1996	Ismail .
5,545,670	8/1996	Bissbort et al. .
5,563,126	10/1996	Allen et al. .
5,597,585	1/1997	Williams et al. .
5,626,883	5/1997	Paul .
5,626,884	5/1997	Lockett .
5,652,261	7/1997	Ismail .
5,656,620	8/1997	Ismail .
5,733,572	3/1998	Unger et al. .
5,770,215	6/1998	Moshyedi .
5,786,384	7/1998	Ismail .
5,795,873	8/1998	Allen .

OTHER PUBLICATIONS

Nelson and Forfar, Associations Between Drugs Administered During Pregnancy And Congenital Abnormalities of the Fetus, British Medical Journal, Mar. 6, 1971, pp. 523–527.

Primary Examiner—James M. Spear
(74) *Attorney, Agent, or Firm*—Alan G. Towner; Eckert Seamans Cherin & Mellott, LLC

(57) **ABSTRACT**

Compounds comprising multi-vitamins, zinc and an anti-platelet aggregating agent for the treatment of atherosclerotic cardiovascular disease (ASCVD) are disclosed. The compounds are provided in dosage form, and preferably include selected amounts of ascorbic acid, folic acid, vitamin E, vitamin B6 and vitamin B12. The anti-platelet aggregating agent preferably comprises aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment of ASCVD, and possess extended shelf lives.

64 Claims, 2 Drawing Sheets